Journal of Nuclear Medicine · 2016 · 36 citations · 9 references
MedicineNuclear MedicineOncologyBreast OncologyMetastasisMolecular ImagingBreast Cancer ImagingBreast Lesion CharacterizationCancer Survival AnalysisMetastatic Breast CancerResponse AssessmentTherapy Response AssessmentBreast Cancer Response AssessmentDisease-specific SurvivalImaging Response CriteriaImaging Response EvaluationPet Response CriteriaTherapy Response EvaluationTreatment Response CriteriaTumor Response Evaluation
UNLABELLED: The PET Response Criteria in Solid Tumors (PERCIST) are not specific regarding the number of lesions that should be analyzed per patient. This study evaluated how the number of analyzed lesions affects response assessment in metastatic breast cancer. METHODS: In 60 patients, response was assessed by the change in SUVpeak, normalized to lean body mass, of the most (18)F-FDG-avid lesion (PERCIST 1) and by the change in the sum of normalized SUVpeak for up to 5 lesions (PERCIST 5). The correlation between response by PERCIST and progression-free and disease-specific survival was evaluated. RESULTS: In responders and nonresponders, the respective progression-free survival at 2 y was 37.26% and 6.43% for PERCIST 1 (P < 0.0001) and 33.65% and 7.14% for PERCIST 5 (P < 0.0001) and the respective disease-specific survival at 4 y was 58.96% and 25.44% for PERCIST 1 (P < 0.012) and 59.12% vs 20.01% for PERCIST 5 (P < 0.002). CONCLUSION: The number of analyzed lesions does not appear to have a major impact on the prognostic value of response assessment with (18)F-FDG PET/CT in metastatic breast cancer.
9
Ian C. P. Smith, A. Welch, Andrew W. Hutcheon et al. · Journal of Clinical Oncology · 2000 · 409 citations
Medicine, Nuclear Medicine, Oncology +17
Joerg Schwarz, M. Bader, Lars Jenicke et al. · PubMed · 2005 · 226 citations
F. Cachin, H. Miles Prince, Annette Hogg et al. · Journal of Clinical Oncology · 2006 · 94 citations · Full text
Medicine, Nuclear Medicine, Oncology +17